Tumor necrosis factor-α (TNF-α) has widespread metabolic actions. Systemic TNF-α administration, however, generates a complex hormonal and metabolic response. Our study was designed to test whether regional, placebo-controlled TNF-α infusion directly affects
insulin resistance and
protein breakdown. We studied eight healthy volunteers once with bilateral femoral vein and artery
catheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp. One artery was perfused with saline and one with TNF-α. During the clamp, TNF-α perfusion increased
glucose arteriovenous differences (0.91 ± 0.17 vs. 0.74 ± 0.15 mmol/L, P = 0.012) and leg
glucose uptake rates. Net
phenylalanine release was increased by TNF-α perfusion with concomitant increases in appearance and disappearance rates.
Free fatty acid kinetics was not affected by TNF-α, whereas
interleukin-6 (IL-6) release increased.
Insulin and
protein signaling in muscle biopsies was not affected by TNF-α. TNF-α directly increased net
muscle protein loss, which may contribute to
cachexia and general
protein loss during severe illness. The finding of increased
insulin sensitivity, which could relate to
IL-6, is of major clinical interest and may concurrently act to provide adequate tissue fuel supply and contribute to the occurrence of systemic
hypoglycemia. This distinct metabolic feature places TNF-α among the rare
insulin mimetics of human origin.